ELISA Kit for Glial Fibrillary Acidic Protein (GFAP)

62.5-4, 000pg/mL

The minimum detectable dose of this kit is typically less than 26.1pg/mL

3h

This assay has high sensitivity and excellent specificity for detection of Glial Fibrillary Acidic Protein (GFAP).
No significant cross-reactivity or interference between Glial Fibrillary Acidic Protein (GFAP) and analogues was observed.

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Glial Fibrillary Acidic Protein (GFAP). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Glial Fibrillary Acidic Protein (GFAP). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Glial Fibrillary Acidic Protein (GFAP), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Glial Fibrillary Acidic Protein (GFAP) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Effects of Exposure to 1-Bromopropane on Astrocytes and Oligodendrocytes in Rat Brain; Effect of memantine, a NMDA receptor blocker, on ethambutol-induced retinal injury; IL-4 Inhibits IL-1β-Induced Depressive-Like Behavior and Central Neurotransmitter Alterations; Protective Effect of Oral Hesperetin Against Unilateral Striatal 6-Hydroxydopamine Damage in the Rat; Hypericum Perforatum Hydroalcoholic Extract Mitigates Motor Dysfunction and is Neuroprotective in Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson’s Disease; Hypericum Perforatum Hydroalcoholic Extract Mitigates Motor Dysfunction and is Neuroprotective in Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson’s Disease; Effect of memantine: A NMDA receptor blocker, on ethambutol-induced retinal injury; ESTROGENIC COMPONENTS FOR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS; Carnosine ameliorates cognitive deficits in streptozotocin-induced diabetic rats: Possible involved mechanisms.; Garlic active constituent s-allyl cysteine protects against lipopolysaccharide-induced cognitive deficits in the rat: Possible involved mechanisms.; Troxerutin exerts neuroprotection in 6-hydroxydopamine lesion rat model of Parkinson's disease: Possible involvement of PI3K/ERβ signaling.; Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.; Estrogen receptors and estetrol-dependent neuroprotective actions: a pilot study.; Soy isoflavone genistein attenuates lipopolysaccharide-induced cognitive impairments in the rat via exerting anti-oxidative and anti-inflammatory effects; Berberine ameliorates intrahippocampal kainate-induced status epilepticus and consequent epileptogenic process in the rat: Underlying mechanisms; The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling.; Acrolein-mediated neurotoxicity in growing Wistar male rats; Berberine ameliorates lipopolysaccharide-induced learning and memory deficit in the rat: insights into underlying molecular mechanisms; Trigonelline protects hippocampus against intracerebral Aβ (1–40) as a model of Alzheimer's disease in the rat: insights into underlying mechanisms;